Elsevier

Neurobiology of Disease

Volume 73, January 2015, Pages 289-295
Neurobiology of Disease

Mice with subtle reduction of NMDA NR1 receptor subunit expression have a selective decrease in mismatch negativity: Implications for schizophrenia prodromal population

https://doi.org/10.1016/j.nbd.2014.10.010Get rights and content

Highlights

  • Mice with subtle reduction of NR1 were tested for schizophrenia-like EEG changes.

  • Measures included P1 and N1 ERP amplitude and gating, MMN and gamma power.

  • Among EEG measures tested, only MMN was disrupted in NR1 heterozygous mice.

  • MMN is the most sensitive EEG measure of subtle reduction in NMDAR function.

Abstract

Reductions in glutamate function are regarded as an important contributory factor in schizophrenia. However, there is a paucity of animal models characterized by developmental and sustained reductions in glutamate function. Pharmacological models using NMDA antagonists have been widely used but these typically produce only transient changes in behavior and brain function. Likewise, mice with homozygous constitutive reductions in glutamate receptor expression show stable brain and behavioral changes, but many of these phenotypes are more severe than the human disease. The current study examines a variety of schizophrenia-related EEG measures in mice with a heterozygous alteration of the NMDA receptor NR1 subunit gene (NR1) that is known to result in reduced NR1 receptor expression in the homozygous mouse (NR1−/−). (NR1+/−) mice showed a 30% reduction in NR1 receptor expression and were reared after weaning in either group or isolated conditions. Outcome measures include the response to paired white noise stimuli, escalating inter-stimulus intervals (ISIs) and deviance-related mismatch negativity (MMN). In contrast to what has been reported in (NR1−/−) mice and mice treated with NMDA antagonists, (NR1+/−) mice showed no change on obligatory Event Related Potential (ERP) measures including the murine P50 and N100 equivalents (P20 and N40), or measures of baseline or evoked gamma power. Alternatively, (NR1+/−) mice showed a marked reduction in response to a deviant auditory tone during MMN task. Data suggest that EEG response to deviant, rather than static, stimuli may be more sensitive for detecting subtle changes in glutamate function. Deficits in these heterozygous NR1 knockdown mice are consistent with data demonstrating MMN deficits among family members of schizophrenia patients and among prodromal patients. Therefore, the current study suggests that (NR1+/−) mice may be among the most sensitive models for increased vulnerability to schizophrenia.

Introduction

Recent evidence suggests that several core feature of schizophrenia may result from decreased glutamatergic activity. Many of the symptoms associated with schizophrenia can be reproduced by administering NMDA antagonists to healthy subjects, and symptom severity in patients are exacerbated following exposure to these agents (Farber, 2003, Javitt and Zukin, 1991, Jentsch and Roth, 1999, Krystal et al., 1994, Lahti et al., 1995, Malhotra et al., 1997, Malhotra et al., 1996). While the psychotomimetic effects of NMDA antagonists were originally emphasized with respect to positive symptoms, much evidence in both laboratory animals and humans now suggests that NMDA antagonism may also contribute to the development of both negative symptoms and cognitive dysfunction (Honey et al., 2003, Honey et al., 2005, Krystal et al., 1994, Malhotra et al., 1996). Such findings have led to a focus on the development of pharmacological methods that model these aspects of schizophrenia symptomology in laboratory animals. To date, several laboratories have demonstrated schizophrenia-like changes on a number of behavioral measures relevant to positive, negative, and cognitive symptoms in laboratory animals exposed to chronic NMDA antagonist administration (Ketamine, PCP or MK801) (Chan et al., 2008, Featherstone et al., 2012, Jentsch and Roth, 1999, Kittelberger et al., 2012, Lazarewicz et al., 2010, Neill et al., 2010, Rushforth et al., 2011, Saunders et al., 2012a, Siegel et al., 2003).

The development of animal models of hypoglutamate function demonstrating stable and reliable changes in behaviors relevant to schizophrenia will be crucial for the development of new approaches for drug discovery in schizophrenia. To this end, we recently assessed a series of electrophysiological and behavioral responses in a transgenic mouse (NR1−/−) that shows only 5–10% normal expression of the NR1 subunit of the NMDA receptor (Bodarky et al., 2009, Gandal et al., 2012a, Gandal et al., 2012b, Halene et al., 2009, Mohn et al., 1999). These NMDAR NR1 deficient mice show disrupted sensory processing, as assessed by auditory event-related potentials (ERPs) or pre-pulse inhibition, reduced behavioral inhibition, and impaired social interaction (Bodarky et al., 2009, Duncan et al., 2004, Duncan et al., 2006, Duncan et al., 2012, Gandal et al., 2012b, Halene et al., 2009, Mohn et al., 1999, Moy et al., 2006). Additionally, NMDAR NR1 deficient mice demonstrate increased resting, and reduced high frequency (gamma, 30–100 Hz) EEG oscillations in response to auditory stimulation (Gandal et al., 2012b). Reduced evoked gamma power has also been widely reported in schizophrenia (Roach and Mathalon, 2008, Spencer et al., 2008, Spencer et al., 2009, Uhlhaas and Singer, 2010), and it has been suggested that this deficit may be the physiological basis for or signifier of impairments observed in schizophrenia. The use of EEG measures such as ERPs and gamma oscillations are important for translational studies since they can easily be measured in both humans and laboratory animals, and because the response of these measures to pharmacological agents and variation in stimulation parameters, including inter-stimulus interval, stimulus intensity, sensory adaptation (a.k.a. gating), and stimulus novelty, all of which show a high degree of similarity across species (Amann et al., 2010, Siegel et al., 2013).

Despite such positive findings, full NR1 hypomorphs may present too severe a phenotype to be relevant for schizophrenia. Homozygous hypomorphs show up to 95% reduced expression of the NMDA NR1 subunit (Mohn et al., 1999), a reduction much greater than what has been shown in post-mortem studies of schizophrenia brains (Gao et al., 2000, Weickert et al., 2013). Additionally, full hypomorphs show phenotypic changes not specific to schizophrenia (Gandal et al., 2012a). In contrast to the full knockdown, we propose that heterozygous (NR1+/−) mice show reductions in NR1 receptor levels that are more consistent with the degree of subtle NMDAR-mediated impairments in glutamate transmission in the human disease. The current study sought to assess the validity of NR1 heterozygous knockout mice as a translational model for subtle reduction in NMDAR function that has been proposed in schizophrenia using EEG and ERP measures that have been well-established for detecting schizophrenia-like changes. Additionally, the additive effects of genetic vulnerability (NR1+/−) and environmental stress (social isolation) were assessed in order to determine the validity of these mice using a two-hit model of schizophrenia vulnerability. Social isolation stress has been associated with the development of schizophrenia-like symptoms both in human populations and laboratory animals (Fone and Porkess, 2008, Geyer et al., 1993, Hodges et al., 1999). Further, the detrimental effects of social isolation are enhanced in rodents with reduced NMDA receptor function (Belforte et al., 2010, Gaskin et al., 2014, Jiang et al., 2013), suggesting that increased susceptibility to environmental insults in patients with schizophrenia might reflect reduced glutamate function. The establishment of a two-hit model combining genetic and environmental insults would be extremely useful for the development of treatments to prevent the development of symptom onset in genetically vulnerable individuals. Given the available evidence, it was predicted that heterozygous NR1 (+/−) mice with reduced glutamate function would be more sensitive to the disruptive effects of social isolation.

Section snippets

Subjects

NR1neo+/− mice (MGI:95819) (Mohn et al., 1999, Duncan et al., 2004, Bickel, 2008) were in-licensed from the laboratory of Dr. Beverly Koller (The University of North Carolina at Chapel Hill) and a breeding colony was established by Astellas Research Institute of America (Skokie, Illinois), maintained at Hilltop Lab Animals (Scottsdale, PA). Mice were maintained on C57BL/6NHla background. The PCR protocol used for genotyping these mice was as follows: NR1 (+) fwd primer (intron 20) 5′TGA GGG GAA

qPCR for NR1 receptor expression

Data were analyzed using a Factorial ANOVA with genotype (NR1 +/− or WT), housing condition (group or isolation) and brain region (DG and PFC) as independent variables and expression level as the dependent variable. NR1 levels were significantly lower in (NR1+/−) relative to wild-type mice (F = 126.3, p < 0.001). There was no main effect of rearing condition, nor was there an interaction between genotype and rearing condition in either brain region. However, there was a significant effect of brain

Discussion

Neither genotype nor rearing condition produced significant reductions in P20 and N40 ERP amplitude in the current study, suggesting that these measures are not sensitive to subtle reductions in NMDA receptor function. The lack of effect on either S1 amplitude on its attenuation is consistent with the finding that disruptions in these measures are typically observed only following relatively high doses of NMDA antagonists (de Bruin et al., 1999, Lazarewicz et al., 2010, Oranje et al., 2002,

Summary and conclusion

The observation that (NR1+/−) mice with subtle reduction in expression of NR1 showed an exclusive deficit on MMN suggests that this measure can be used to detect subtle alterations in glutamate function that are not detected using alternate EEG measures. As such, the MMN may be an important biomarker of early alterations, as may occur during the prodromal period (Perez et al., 2014).

Acknowledgment

Funding provided by 5R01DA023210-02 (SJS) and an investigator initiated research grant from Astellas (SJS) (10031929). J. Kogan, R. Shin and M. Matsumoto are employees of Astellas Research Institute of America.

References (67)

  • Z. Jiang

    Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons

    Biol. Psychiatry

    (2013)
  • A.C. Lahti

    Subanesthetic doses of ketamine stimulate psychosis in schizophrenia

    Neuropsychopharmacology

    (1995)
  • A.K. Malhotra

    NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers

    Neuropsychopharmacology

    (1996)
  • A.R. Mohn

    Mice with reduced NMDA receptor expression display behaviors related to schizophrenia

    Cell

    (1999)
  • S.S. Moy

    Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function

    Brain Res.

    (2006)
  • J.C. Neill

    Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism

    Pharmacol. Ther.

    (2010)
  • B. Oranje

    Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol

    Biol. Psychiatry

    (2002)
  • V.B. Perez

    Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity

    Biol. Psychiatry

    (2014)
  • D. Pinault

    N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex

    Biol. Psychiatry

    (2008)
  • J.A. Saunders

    NMDA antagonist MK801 recreates auditory electrophysiology disruption present in autism and other neurodevelopmental disorders

    Behav. Brain Res.

    (2012)
  • J.A. Saunders

    NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia

    Neurobiol. Dis.

    (2012)
  • K.M. Spencer

    Sensory-evoked gamma oscillations in chronic schizophrenia

    Biol. Psychiatry

    (2008)
  • D. Umbricht

    Effects of clozapine on auditory event-related potentials in schizophrenia

    Biol. Psychiatry

    (1998)
  • M.M. Behrens

    Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase

    Science

    (2007)
  • J.E. Belforte

    Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes

    Nat. Neurosci.

    (2010)
  • S. Bickel

    Early auditory sensory processing deficits in mouse mutants with reduced NMDA receptor function

    Neuropsychopharmacology

    (2008)
  • E.N. Billingslea

    Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits

    Neuropsychopharmacology

    (2014)
  • C.L. Bodarky

    Novel environment and GABA agonists alter event-related potentials in N-methyl-d-aspartate NR1 hypomorphic and wild-type mice

    J. Pharmacol. Exp. Ther.

    (2009)
  • M.H. Chan

    Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice

    Psychopharmacology (Berl.)

    (2008)
  • N.M. de Bruin

    Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats

    Psychopharmacology (Berl.)

    (1999)
  • G.E. Duncan

    Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function

    Psychopharmacology (Berl.)

    (2006)
  • R.S. Ehrlichman

    Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice

    J. Cogn. Neurosci.

    (2008)
  • N.B. Farber

    The NMDA receptor hypofunction model of psychosis

    Ann. N. Y. Acad. Sci.

    (2003)
  • Cited by (0)

    View full text